Medivir AB: HELIX-2, A Phase II All-Oral Combination Study Of Simeprevir, TMC647055 And Samatasvir (IDX719) For The Treatment Of Hepatitis C Has Been Initiated

Published: Dec 02, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!


Medivir AB (OMX: MVIR)(STO:MVIR-B), announces that IDENIX has initiated a phase II clinical trial (HELIX-2) evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of simeprevir, samatasvir and TMC647055 with a pharmacokinetic enhancer.

The HELIX-2 trial is a 12-week, randomized, open-label study evaluating the efficacy, safety and tolerability of simeprevir, TMC647055 and samatasvir. The trial will evaluate genotype 1 HCV-infected patients who are either treatment-naïve or who have relapsed after prior treatment with interferon and ribavirin. Patients will receive 75 mg of simeprevir, 50 mg samatasvir and 450 mg of TMC647055 plus a low dose of ritonavir as a pharmacokinetic enhancer, each once daily for 12 weeks, with or without the addition of ribavirin.

Help employers find you! Check out all the jobs and post your resume.

Back to news